Minor
ReVeRA-301 · Etripamil in Atrial Fibrillation Phase 3
Trial sites expanded: 11 → 15 locations
And 1 more change in the last 30 days
Milestone Pharmaceuticals Inc.Phase 3 NCT06716021 Registry history of NCT06716021 on ClinicalTrials.gov (opens the registry)